Expert perspectives on barriers and enablers in policy and infrastructure
This webinar brings together leaders in policy, ethics, advocacy, and regulation to examine what must change to facilitate equitable access to cell and gene therapy today. Hear from:
Dr. Alison Bateman-House, NYU Grossman School of Medicine
Annie Kennedy, EveryLife Foundation for Rare Diseases
Monica Veldman, Alliance for Regenerative Medicine
Max Bronstein, Aviva Strategies
The discussion covers regulatory uncertainty and FDA capacity challenges in 2025, rare pediatric incentives and why the priority review voucher (PRV) matters for development viability, evidence expectations for rare disease trials, operational barriers to access and uptake of therapies, and the role patient advocacy plays throughout CGT development.
